139 related articles for article (PubMed ID: 31967294)
1. The pro- and anti-cancer effects of oxycodone are associated with epithelial growth factor receptor level in cancer cells.
Yu Y; Li D; Duan J; Xu H; Li L; Tan D; Yan H
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31967294
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
Chen J; Wang W; Wang H; Liu X; Guo X
Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid receptor-dependent activation of EGFR.
Xiao K; Zheng Q; Bao L
BMC Anesthesiol; 2022 Aug; 22(1):268. PubMed ID: 35999506
[TBL] [Abstract][Full Text] [Related]
5. Oxycodone stimulates normal and malignant hematopoietic progenitors via opioid-receptor-independent-β-catenin activation.
Hu N; Yu T; Chen J; Zheng S; Yan H; Duan J
Biochem Biophys Res Commun; 2020 Dec; 533(4):1457-1463. PubMed ID: 33268026
[TBL] [Abstract][Full Text] [Related]
6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
7. Chronic oxycodone induces integrated stress response in rat brain.
Fan R; Schrott LM; Snelling S; Ndi J; Arnold T; Korneeva NL
BMC Neurosci; 2015 Sep; 16():58. PubMed ID: 26377394
[TBL] [Abstract][Full Text] [Related]
8. Oxycodone. Pharmacological profile and clinical data in chronic pain management.
Coluzzi F; Mattia C
Minerva Anestesiol; 2005; 71(7-8):451-60. PubMed ID: 16012419
[TBL] [Abstract][Full Text] [Related]
9. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
[TBL] [Abstract][Full Text] [Related]
10. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
12. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated.
Ross FB; Smith MT
Pain; 1997 Nov; 73(2):151-157. PubMed ID: 9415500
[TBL] [Abstract][Full Text] [Related]
13. Morphine stimulates cervical cancer cells and alleviates cytotoxicity of chemotherapeutic drugs via opioid receptor-dependent and -independent mechanisms.
Yu Z; Jin S; Tian S; Wang Z
Pharmacol Res Perspect; 2022 Oct; 10(5):e01016. PubMed ID: 36200813
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways.
Kang N; Zhang JH; Qiu F; Tashiro S; Onodera S; Ikejima T
Cancer Lett; 2010 Aug; 294(2):147-58. PubMed ID: 20202741
[TBL] [Abstract][Full Text] [Related]
15. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
[TBL] [Abstract][Full Text] [Related]
18. Oxycodone suppresses the apoptosis of hippocampal neurons induced by oxygen-glucose deprivation/recovery through caspase-dependent and caspase-independent pathways via κ- and δ-opioid receptors in rats.
Kong C; Miao F; Wu Y; Wang T
Brain Res; 2019 Oct; 1721():146319. PubMed ID: 31276638
[TBL] [Abstract][Full Text] [Related]
19. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
20. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy.
Davis MP; Varga J; Dickerson D; Walsh D; LeGrand SB; Lagman R
Support Care Cancer; 2003 Feb; 11(2):84-92. PubMed ID: 12560936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
